Defining efficacy

When Idec Pharmaceuticals Corp. and partner SmithKline Beecham selected IDEC-151 clenoliximab as their lead anti-CD4 antibody to treat rheumatoid arthritis, the choice was predicated on IDEC-151 being superior to the former antibody (IDEC-CE9.1) in terms of a

Read the full 373 word article

How to gain access

Continue reading with a
two-week free trial.